Kilitch Drugs (India) Limited (KILITCH) Fair Value & Analysis

Healthcare · IN · Market cap ₹6.9B

Below-average quality, and screening another 19% overvalued on our models.

What matters now

• Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts.
• Our model range runs from ₹102.95 (bear) to ₹179.86 (bull), base ₹139.77. The closer the price sits to the lower half, the larger the margin of safety.
• Quality 32/100 (below-average quality) with high evidence: the data supports the verdict.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range ₹51.65 – ₹243.93 · fair‑value band ₹102.95 – ₹179.86 · the ₹172.58 price screens above the ₹139.77 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Kilitch Drugs (India) Limited (KILITCH) currently trades at ₹172.58, while our model-based Fair Value estimate is ₹139.77, implying the stock looks roughly 19.0% overvalued today. The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Kilitch Drugs (India) Limited generated revenue of ₹2.4B at a net margin of 12.8%. Revenue grew 46.3% year over year. It earns a return on equity of 12.4%. Net debt stands at ₹719M. Fundamentals as of Aug 13, 2026

Our scenario range runs from ₹102.95 (bear case) to ₹179.86 (bull case); at ₹172.58, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 31% below its 52-week high and 47% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -19%, KILITCH screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Growth Earnings (₹233.56) versus Dividend Discount (₹5.18). Highest evidence: Residual Income (76).

Key figures & financial health

Quality Score breakdown

About the company

Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally.

Full company description

Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, anticoagulant, narcotic, oncology, ophthalmic, antifungal, corticosteroid, anticoagulant, and other applications, as well as vaccines, veterinary products, iron supplements for anemia, Klavmox, and Onecef. It also provides oral formulations, including tablets, capsules, dry syrup, and oral powder for antibiotic, anti-diabetic, cardiovascular, and other areas; effervescent tablets and powders, such as Roipar, Duregra, and Roivit; and nutritional products, including Celtine. In addition, the company offers cosmetics, which include oil, lotion, liquid to cream, paste in skin, and personal and hair care products; herbal products for use in sore throat and prostate problems, as well as a supplement for diabetes, obesity, libido, and other conditions; ortho rehabilitation and implants; and medical devices comprising C-Seal, a skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Further, it provides PH-7 which reduces acid content of the stomach; SRO kit for treating childhood diarrhea; 9-VIT for use in surgery, extensive burns, fractures, and other trauma; and HPURE for sore throat and cough. The company exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Kilitch Drugs (India) Limited reported revenue of ₹2.4B in FY2026 versus ₹1.1B in FY2022, a compound +19.8%/yr. Reported net income was ₹302M in FY2026, compounding +42.3%/yr from FY2022.

KILITCH screens 19% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →

Peer Group

Drug Manufacturers - Specialty & Generic · 625 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.